ScholarIQanswers from OpenAlex & ORCID
David A. Reardon
ResearcherPublications, citations & collaboration network
David A. Reardon is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David A. Reardon have?
ScholarIQindexed works
David A. Reardon has 1,228 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David A. Reardon have?
ScholarIQcitation count
David A. Reardon has 63,984 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David A. Reardon?
ScholarIQh-index
David A. Reardon has an h-index of 120 in OpenAlex.
What is the i10-index of David A. Reardon?
ScholarIQi10-index
David A. Reardon has an i10-index of 456 in OpenAlex.
What is the ORCID of David A. Reardon?
ScholarIQorcid
The ORCID for David A. Reardon is on the source record.
What is the OpenAlex record for David A. Reardon?
ScholarIQopenalex
The OpenAlex for David A. Reardon is on the source record.
What are the most-cited papers on David A. Reardon?
ScholarIQmost cited works
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Alex Lee, Tom B. Davidson, Anthony Wang, Benjamin M. Ellingson, Julie Rytlewski, Catherine Sanders, Eric S. Kawaguchi, Lin Du, Gang Li, William H. Yong, Sarah Gaffey, Adam L. Cohen, Ingo K. Mellinghoff, Eudocia Q. Lee, David A. Reardon, Barbara O’Brien, Nicholas Butowski, Phioanh L. Nghiemphu, Jennifer Clarke, Isabel Arrillaga‐Romany, Howard Colman, Thomas Kaley, John de Groot, Linda M. Liau, Patrick Y. Wen, Robert M. Prins
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada, Michael Weller, Raymond Y. Huang, Gaetano Finocchiaro, Mark R. Gilbert, Wolfgang Wick, Benjamin M. Ellingson, Naoya Hashimoto, Ian F. Pollack, Alba A. Brandes, Enrico Franceschi, Christel Herold‐Mende, Lakshmi Nayak, Ashok Panigrahy, Whitney B. Pope, Robert M. Prins, John H. Sampson, Patrick Y. Wen, David A. Reardon
Mechanisms and therapeutic implications of hypermutation in gliomas
Mehdi Touat, Yvonne Y. Li, Adam N. Boynton, Liam F. Spurr, J. Bryan Iorgulescu, Craig L. Bohrson, Isidro Cortés‐Ciriano, Cristina Birzu, Jack Geduldig, Kristine Pelton, Mary Jane Lim-Fat, Sangita Pal, Rubén Ferrer-Luna, Shakti Ramkissoon, Frank Dubois, Charlotte Bellamy, Naomi Currimjee, Juliana Bonardi, Kenin Qian, Patricia Ho, Seth Malinowski, Léon Taquet, Robert E. Jones, Aniket Shetty, Kin-Hoe Chow, Radwa Sharaf, Dean C. Pavlick, Lee A. Albacker, Nadia Younan, Capucine Baldini, Maïté Verreault, Marine Giry, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agustí Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle–Donadey, Dimitri Psimaras, Eudocia Q. Lee, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S. Barnholtz‐Sloan, Arnab Chakravarti, Wenya Linda Bi, E. Antonio Chiocca, Katie Fehnel, Sanda Alexandrescu, N. Susan, Daphne A. Haas‐Kogan, Tracy T. Batchelor, Garrett M. Frampton, Brian M. Alexander, Raymond Y. Huang, Azra H. Ligon, Florence Coulet, Jean‐Yves Delattre, Khê Hoang‐Xuan, David M. Meredith, Sandro Santagata, Alex Duval, Marc Sanson, Andrew D. Cherniack, Patrick Y. Wen, David A. Reardon, Aurélien Marabelle, Peter J. Park, Ahmed Idbaïh, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L. Ligon
Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco, H. Ian Robins, Daniel Rohle, Carl Campos, Christian Grommes, Phioanh L. Nghiemphu, Sara Kubek, Barbara Oldrini, Milan G. Chheda, Nicolas A. Yannuzzi, Hui Tao, Shaojun Zhu, Akio Iwanami, Daisuke Kuga, Julie Dang, Alicia Pedraza, Cameron Brennan, Adriana Heguy, Linda M. Liau, Frank S. Lieberman, W.K. Alfred Yung, Mark R. Gilbert, David A. Reardon, Jan Drappatz, Patrick Y. Wen, Kathleen R. Lamborn, Susan M. Chang, Michael D. Prados, Howard A. Fine, Steve Horvath, Nian Wu, Andrew B. Lassman, Lisa M. DeAngelis, William H. Yong, John G. Kuhn, Paul S. Mischel, Minesh P. Mehta, Timothy F. Cloughesy, Ingo K. Mellinghoff
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak, Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Coté, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon